|
Mantle cell lymphoma is an aggressive form of B-cell non-Hodgkin lymphoma (NHL). It is a relatively rare disease, constituting only about 6% of all NHL cases in the United States or about 3,000 cases per year.
The Mantle Cell Lymphoma Consortium (MCLC) was formed in January 2005 by the Lymphoma Research Foundation (LRF) and is composed of more than 100 laboratory and clinical scientists from North America and Europe focusing their research efforts on mantle cell lymphoma. The MCLC is a program designed to accelerate the pace of research in mantle cell lymphoma. Our goal is to identify effective and curative treatment strategies for mantle cell lymphoma by funding innovative clinical studies.
To receive a copy of the 2010 Workshop summary, please click here and download the Spring 2010 issue of Research Report. Other back issues of this publication are also available to view.
NEW MCL GRANT ANNOUNCEMENTS!
>>
2010 MANTLE CELL LYMPHOMA CONSORTIUM SCIENTIFIC WORKSHOP CONCLUDES IN ATLANTA WITH 33 PRESENTATIONS AND AMPLE COLLABORATION
The seventh meeting of the MCLC concludes after 33 diverse presentations, lively discussion and a wealth of new ideas. >>
The Lymphoma Research Foundation is pleased to acknowledge the sponsors for our 2010 Mantle Cell Lymphoma Workshop: Millennium – The Takeda Oncology Company and Celgene Corporation for their support and continuing contributions to LRF and our efforts to cure lymphoma.
Featured Researcher
Dr. Brad Kahl, MCLC Executive Committee member, was recently named chair of the ECOG lymphoma committee. Read about his journey to this point.
Mantle Cell Lymphoma News & Updates
- LRF CDA results in clinical trial >>
- MCL Highlights from ASCO >>
- Lenalidomide produces high response rate >>
- LRF's 6th MCL Consortium Scientific Workshop >>
- What has the MCL Consortium been up to? >>
- MCL Consortium Chair discusses curent state of MCL >>
- Clinical Trial Update >>
- 30 Years of Progress >>
|
